Literature DB >> 30844410

Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders.

Elizabeth S Smith1, Joshua E Porterfield2, Rangaramanujam M Kannan3.   

Abstract

Nanotechnology has the potential to open many novel diagnostic and treatment avenues for disorders of the central nervous system (CNS). In this review, we discuss recent developments in the applications of nanotechnology in CNS therapies, diagnosis and biology. Novel approaches for the diagnosis and treatment of neuroinflammation, brain dysfunction, psychiatric conditions, brain cancer, and nerve injury provide insights into the potential of nanomedicine. We also highlight nanotechnology-enabled neuroscience techniques such as electrophysiology and intracellular sampling to improve our understanding of the brain and its components. With nanotechnology integrally involved in the advancement of basic neuroscience and the development of novel treatments, combined diagnostic and therapeutic applications have begun to emerge. Nanotheranostics for the brain, able to achieve single-cell resolution, will hasten the rate in which we can diagnose, monitor, and treat diseases. Taken together, the recent advances highlighted in this review demonstrate the prospect for significant improvements to clinical diagnosis and treatment of a vast array of neurological diseases. However, it is apparent that a strong dialogue between the nanoscience and neuroscience communities will be critical for the development of successful nanotherapeutics that move to the clinic, benefit patients, and address unmet needs in CNS disorders.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Central nervous system; Glioblastoma; Nanomedicine; Nerve repair; Neurodegeneration; Neuroinflammation; Psychiatric disorders; Theranostics; Translational medicine

Mesh:

Substances:

Year:  2019        PMID: 30844410      PMCID: PMC7043366          DOI: 10.1016/j.addr.2019.02.009

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  223 in total

Review 1.  Pathoanatomy of Parkinson's disease.

Authors:  H Braak; E Braak
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

Review 2.  Nanoparticle technology for treatment of Parkinson's disease: the role of surface phenomena in reaching the brain.

Authors:  Gerardo Leyva-Gómez; Hernán Cortés; Jonathan J Magaña; Norberto Leyva-García; David Quintanar-Guerrero; Benjamín Florán
Journal:  Drug Discov Today       Date:  2015-02-17       Impact factor: 7.851

3.  Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers.

Authors:  Jason Allen; Ryan D Bradley
Journal:  J Altern Complement Med       Date:  2011-09       Impact factor: 2.579

4.  Microglial cells contribute to endogenous brain defenses after acute neonatal focal stroke.

Authors:  Joel V Faustino; Xia Wang; Cali E Johnson; Alexander Klibanov; Nikita Derugin; Michael F Wendland; Zinaida S Vexler
Journal:  J Neurosci       Date:  2011-09-07       Impact factor: 6.167

5.  64Cu-Labeled multifunctional dendrimers for targeted tumor PET imaging.

Authors:  Wenhui Ma; Fanfan Fu; Jingyi Zhu; Rui Huang; Yizhou Zhu; Zhenwei Liu; Jing Wang; Peter S Conti; Xiangyang Shi; Kai Chen
Journal:  Nanoscale       Date:  2018-03-29       Impact factor: 7.790

6.  In vivo proinflammatory activity of generations 0-3 (G0-G3) polyamidoamine (PAMAM) nanoparticles.

Authors:  Isabelle Durocher; Denis Girard
Journal:  Inflamm Res       Date:  2016-06-23       Impact factor: 4.575

7.  Nanoparticle-induced neuronal toxicity across placental barriers is mediated by autophagy and dependent on astrocytes.

Authors:  Simon J Hawkins; Lucy A Crompton; Aman Sood; Margaret Saunders; Noreen T Boyle; Amy Buckley; Aedín M Minogue; Sarah F McComish; Natalia Jiménez-Moreno; Oscar Cordero-Llana; Petros Stathakos; Catherine E Gilmore; Stephen Kelly; Jon D Lane; C Patrick Case; Maeve A Caldwell
Journal:  Nat Nanotechnol       Date:  2018-04-02       Impact factor: 39.213

8.  Brain targeted oral delivery of doxycycline hydrochloride encapsulated Tween 80 coated chitosan nanoparticles against ketamine induced psychosis: behavioral, biochemical, neurochemical and histological alterations in mice.

Authors:  Monu Yadav; Milind Parle; Nidhi Sharma; Sameer Dhingra; Neha Raina; Deepak Kumar Jindal
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

9.  Targeted genetic manipulations of neuronal subtypes using promoter-specific combinatorial AAVs in wild-type animals.

Authors:  Heinrich S Gompf; Evgeny A Budygin; Patrick M Fuller; Caroline E Bass
Journal:  Front Behav Neurosci       Date:  2015-07-02       Impact factor: 3.558

10.  2D and 3D cell cultures - a comparison of different types of cancer cell cultures.

Authors:  Marta Kapałczyńska; Tomasz Kolenda; Weronika Przybyła; Maria Zajączkowska; Anna Teresiak; Violetta Filas; Matthew Ibbs; Renata Bliźniak; Łukasz Łuczewski; Katarzyna Lamperska
Journal:  Arch Med Sci       Date:  2016-11-18       Impact factor: 3.318

View more
  6 in total

1.  Dendrimer-2PMPA Delays Muscle Function Loss and Denervation in a Murine Model of Amyotrophic Lateral Sclerosis.

Authors:  Carolyn Tallon; Anjali Sharma; Zhi Zhang; Ajit G Thomas; Justin Ng; Xiaolei Zhu; Amanda Donoghue; Michael Schulte; Tawnjerae R Joe; Siva P Kambhampati; Rishi Sharma; Kevin Liaw; Sujatha Kannan; Rangaramanujam M Kannan; Barbara S Slusher
Journal:  Neurotherapeutics       Date:  2022-01-04       Impact factor: 6.088

Review 2.  Review of nanotheranostics for molecular mechanisms underlying psychiatric disorders and commensurate nanotherapeutics for neuropsychiatry: The mind knockout.

Authors:  Rajiv Kumar; Bhupender S Chhikara; Kiran Gulia; Mitrabasu Chhillar
Journal:  Nanotheranostics       Date:  2021-03-01

3.  Systemic administration of dendrimer N-acetyl cysteine improves outcomes and survival following cardiac arrest.

Authors:  Hiren R Modi; Qihong Wang; Sarah J Olmstead; Elizabeth S Khoury; Nirnath Sah; Yu Guo; Payam Gharibani; Rishi Sharma; Rangaramanujam M Kannan; Sujatha Kannan; Nitish V Thakor
Journal:  Bioeng Transl Med       Date:  2021-10-13

4.  Catalytically active gold clusters with atomic precision for noninvasive early intervention of neurotrauma.

Authors:  Yunguang Zhang; Si Sun; Haile Liu; Qinjuan Ren; Wenting Hao; Qi Xin; Jiangang Xu; Hao Wang; Xiao-Dong Zhang
Journal:  J Nanobiotechnology       Date:  2021-10-13       Impact factor: 10.435

5.  Neuroprotective effects of a dendrimer-based glutamate carboxypeptidase inhibitor on superoxide dismutase transgenic mice after neonatal hypoxic-ischemic brain injury.

Authors:  O Arteaga Cabeza; Z Zhang; E Smith Khoury; R A Sheldon; A Sharma; F Zhang; B S Slusher; R M Kannan; S Kannan; D M Ferriero
Journal:  Neurobiol Dis       Date:  2020-11-30       Impact factor: 5.996

6.  Disease-directed engineering for physiology-driven treatment interventions in neurological disorders.

Authors:  Thomas Wood; Elizabeth Nance
Journal:  APL Bioeng       Date:  2019-10-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.